Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Malignant Tumors: Mechanistic Insights, Clinical Efficacy, and Emerging Optimization Strategies

Authors

  • Jiatong Chen
  • Weihui Wang

DOI:

https://doi.org/10.54097/jdh0fj75

Keywords:

Tumor Immunology, CAR-T Immunotherapy, Chimeric Antigen Receptor T Cells, Solid Tumors, Clinical Application

Abstract

CAR-T cell therapy has been proven to show favorable efficacy in various hematological malignancies, particularly in acute lymphoblastic leukemia, multiple myeloma, and myelodysplastic syndromes, with promising results also observed in chronic lymphocytic leukemia. Additionally, CAR-T cell therapy can be applied in the treatment of multiple diseases such as hematological tumors and solid tumors, independent of factors including tumor type, patient age, tumor stage, and treatment response. This article outlines the definition, development history, basic principles of CAR-T cell therapy, and its significance in tumor treatment. It further discusses in detail the structure and function of CAR-T cells, their preparation process, clinical applications, safety, and side effects. Finally, the prospects and future directions of CAR-T cell therapy are explored.

Downloads

Download data is not yet available.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians, 2021, 71(3): 209-249.

[2] Dabas P, Danda A. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy[J]. Medical Oncology, 2023, 40(9): 275.

[3] Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86(24): 10024-10028.

[4] Mullard A. FDA approves first CAR T therapy[J]. Nature Reviews Drug Discovery, 2017, 16(10): 669. DOI: 10.1038/nrd.2017.191.

[5] [Anonymous]. First-Ever CAR T-cell Therapy Approved in U.S.[J]. Cancer Discovery, 2017, 7(10): OF1. DOI: 10.1158/2159-8290.CD-NB2017-126.

[6] Miliotou A N, Papadopoulou L C. CAR T-cell Therapy: A New Era in Cancer Immunotherapy[J]. Current Pharmaceutical Biotechnology, 2018, 19(1): 5-18.

[7] Dunn G P, Bruce A T, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape[J]. Nature Immunology, 2002, 3(11): 991-998.

Downloads

Published

28-08-2025

Issue

Section

Articles

How to Cite

Chen, J., & Wang, W. (2025). Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Malignant Tumors: Mechanistic Insights, Clinical Efficacy, and Emerging Optimization Strategies. International Journal of Biology and Life Sciences, 11(3), 62-65. https://doi.org/10.54097/jdh0fj75